Amir S. Steinberg
- ASSISTANT PROFESSOR Medicine, Hematology and Medical Oncology
American Board of Internal Medicine
MD, Texas Tech Univ. Health Science Ctr
B.A.,, the University of Texas,
Major:History, Minor:Biology, PreMed,
M.D.,, Texas Tech University School of Medicine,
Residency, Internal Medicine
St. Lukes Roosevelt Hospital
Lenox Hill Hospital
Fellowship, Bone Marrow Trans.
Stanford University Hospital
Amir Steinberg, MD, FACP, is an assistant professor in the division of hematology-oncology at Mount Sinai Hospital. Dr. Steinberg will be working primarily in hematologic malignancies and stem cell transplantation. He previously was a clinical assistant professor at UCLA on the staff of Cedars-Sinai Medical Center in Los Angeles. where his research focused on nonmyeloablative stem cell transplants for acute leukemia and novel therapies for relapsed central nervous system lymphomas. He also has a clinical interest in cancer survivorship as he is a lymphoma survivor himself.
A native Texan, Dr. Steinberg graduated magna cum laude from the University of Texas, Austin, with a bachelor's in history and a minor in biology. He earned his medical degree from Texas Tech University School of Medicine, completing his residency in internal medicine at St. Luke's-Roosevelt Hospital, a teaching hospital of Columbia University, and a fellowship in hematology-oncology at Lenox Hill Hospital. Subsequently, Dr. Steinberg completed a bone marrow transplant fellowship at Stanford University Hospital and Clinics in Palo Alto, California. Dr. Steinberg is board-certified in Medical Oncology, Hematology, and Internal Medicine.
Fellow of the American College of Physicians (FACP)
American College of Physicians (ACP)
Award of Excellence,
Southern California Cancer Pain Initiative,
Kim D, Bahadini B, Steinberg A, Steinberg A. Simultaneous acute myeloid leukemia and multiple myeloma successfully treated with allogeneic stem cell transplantation. Southern medical journal 2009 Dec; 7(12).
Steinberg A. First reported case of aplastic anemia occurring in a patient after acute promyelocytic leukemia in remission. 2009 Oct; 7.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr. Steinberg did not report having any of the following types of financial relationships with industry during 2012 and/or 2013: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website at http://icahn.mssm.edu/about-us/services-and-resources/faculty-resources/handbooks-and-policies/faculty-handbook. Patients may wish to ask their physician about the activities they perform for companies.
Icahn Medical Institute Floor 3rd Floor Room 3-29
1425 Madison Avenue
New York, NY 10029
1470 Madison Avenue
New York, NY 10029